ECM
FDMT icon

ExodusPoint Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

ExodusPoint Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145K Sell
15,529
-23,646
-60% -$206K ﹤0.01% 1413
2025
Q4 		$294K Buy
+39,175
New +$397K ﹤0.01% 1316
2024
Q3 		– Sell
-49,945
Closed -$1.05M – 1767
2024
Q2 		$1.05M Buy
+49,945
New +$1.25M 0.01% 1011
2023
Q4 		– Sell
-29,307
Closed -$373K – 1654
2023
Q3 		$373K Buy
+29,307
New +$490K ﹤0.01% 1340
2021
Q1 		– Sell
-33,152
Closed -$1.37M – 2255
2020
Q4 		$1.37M Buy
+33,152
New +$1.37M 0.02% 700

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return